Institute of Respiratory Disease, Chongqing Xinqiao Hospital, Third Military Medical University, Chongqing, China.
Eur J Cardiothorac Surg. 2013 May;43(5):1028-35. doi: 10.1093/ejcts/ezs481. Epub 2012 Aug 31.
Postimplantation right ventricular dysfunction is associated with increased morbidity and mortality in ventricular assist device (VAD) recipients. This study aimed to determine the preoperative risk factors for severe right heart failure needing biventricular mechanical circulatory support in children with end-stage heart failure.
We reviewed data from 84 children supported with long-term VADs at the German Heart Institute Berlin between January 1999 and October 2010. Right ventricular assist device (RVAD) support was needed for 24 (29%) patients, and the other 60 (71%) were implanted with left ventricular assist devices (LVADs).
The median age at implantation was 7 years (12 days-18 years), and the median support time was 41 days (1-432 days). Of the 84 patients, the overall survival to transplantation or recovery of ventricular function was 69%. Compared with children implanted with LVAD, patients receiving biventricular support had significantly higher postoperative mortality (P = 0.04). The multivariate logistic regression indicated that decreased milrinone use was the only preoperative factor independently associated with increased requirement for biventricular support (odds ratio: 0.1, 95% confidence interval: 0.04-0.64, P = 0.01). Children treated with milrinone preoperatively showed improved survival after implantation (P = 0.04).
Paediatric patients needing biventricular support had significantly higher postoperative mortality. Preoperative milrinone use might decrease the risk of severe right ventricular failure requiring additional RVAD insertion and improve postimplantation survival in children with advanced heart failure.
心脏辅助装置(VAD)植入后的右心室功能障碍与发病率和死亡率增加有关。本研究旨在确定终末期心力衰竭儿童中需要双心室机械循环支持的严重右心衰竭的术前危险因素。
我们回顾了 1999 年 1 月至 2010 年 10 月期间在德国柏林心脏研究所接受长期 VAD 支持的 84 名儿童的数据。24 名(29%)患者需要右心室辅助装置(RVAD)支持,其余 60 名(71%)患者植入左心室辅助装置(LVAD)。
植入时的中位年龄为 7 岁(12 天-18 岁),中位支持时间为 41 天(1-432 天)。84 名患者中,整体移植或心室功能恢复的存活率为 69%。与植入 LVAD 的儿童相比,接受双心室支持的患者术后死亡率显著更高(P = 0.04)。多变量逻辑回归表明,米力农的使用减少是唯一与增加双心室支持需求相关的术前因素(比值比:0.1,95%置信区间:0.04-0.64,P = 0.01)。术前接受米力农治疗的儿童在植入后存活率提高(P = 0.04)。
需要双心室支持的儿科患者术后死亡率显著更高。术前米力农的使用可能会降低严重右心室衰竭需要额外 RVAD 插入的风险,并改善晚期心力衰竭儿童的植入后存活率。